Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide. In company-funded studies, participants taking Wegovy had average weight loss of 15%, about 34 pounds (15.3 kilograms). […]
The FDA approved of new drug, Wegovy, to be sold in the U.S. and marketed for weight loss. The drug has been modified from Novo Nordisk s diabetes drug semaglutide.
Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. The Food and Drug Administration